Roles of calcium regulating MicroRNAs in cardiac ischemia-reperfusion injury

Cells

Volumn 3, Issue 3, 2014, Pages 899-913

  Choi, Eunhyun ^a   Cha, Min Ji ^a   Hwang, Ki Chul ^a  

^a Catholic Kwandong University   (South Korea)

Author keywords

Ca2+; Calcium; Heart; MicroRNA; Myocardial ischemia reperfusion injury

Indexed keywords

ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKER; CALCINEURIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM ION; CALMODULIN; MICRORNA; MICRORNA 1; MICRORNA 144; MICRORNA 145; MICRORNA 15A; MICRORNA 21; MICRORNA 214; MICRORNA 25; MICRORNA 451; MICRORNA 494; MICRORNA 574 3P; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PHOSPHOLAMBAN; SODIUM CALCIUM EXCHANGE PROTEIN; UNCLASSIFIED DRUG;

CALCIUM HOMEOSTASIS; CALCIUM SIGNALING; CELL ENERGY; GENE EXPRESSION; HEART CONTRACTION; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; NONHUMAN; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW;

EID: 85056746586     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells3030899     Document Type: Review

References (83)

1. 2+handling in heart failure. Circ. Res. 2013, 113, 690–708.
2. Buja, L.M. Myocardial ischemia and reperfusion injury. Cardiovasc. Pathol. 2005, 14, 170–175.
3. Viola, H.M.; Hool, L.C. How does calcium regulate mitochondrial energetics in the heart?—New insights. Heart Lung Circ. 2014, 23, 602–609.
4. Kho, C.; Lee, A.; Hajjar, R.J. Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy. Nat. Rev. Cardiol. 2012, 9, 717–733.
5. Peterson, S.M.; Thompson, J.A.; Ufkin, M.L.; Sathyanarayana, P.; Liaw, L.; Congdon, C.B. Common features of microRNA target prediction tools. Front. Genet. 2014, 5, 23.
6. Choi, E.; Choi, E.; Hwang, K.C. MicroRNAs as novel regulators of stem cell fate. World J. Stem Cell. 2013, 5, 172–187.
7. Macfarlane, L.A.; Murphy, P.R. MicroRNA: Biogenesis, function and role in cancer. Curr. Genom. 2010, 11, 537–561.
8. Elramah, S.; Landry, M.; Favereaux, A. MicroRNAs regulate neuronal plasticity and are involved in pain mechanisms. Front. Cell. Neurosci. 2014, 8, doi: 10.3389/fncel.2014.00031.
9. Di Leva, G.; Garofalo, M.; Croce, C.M. MicroRNAs in cancer. Annu. Rev. Pathol. 2014, 9, 287–314.
10. Winter, J.; Jung, S.; Keller, S.; Gregory, R.I.; Diederichs, S. Many roads to maturity: MicroRNA biogenesis pathways and their regulation. Nat. Cell Biol. 2009, 11, 228–234.
11. Harada, M.; Luo, X.; Murohara, T.; Yang, B.; Dobrev, D.; Nattel, S. MicroRNA regulation and cardiac calcium signaling: Role in cardiac disease and therapeutic potential. Circ. Res. 2014, 114, 689–705.
12. Aghabozorg Afjeh, S.S.; Ghaderian, S.M. The role of microRNAs in cardiovascular disease. Int. J. Mol. Cell. Med. 2013, 2, 50–57.
13. Ling, H.; Fabbri, M.; Calin, G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 2013, 12, 847–865.
14. Vickers, K.C.; Rye, K.A.; Tabet, F. MicroRNAs in the onset and development of cardiovascular disease. Clin. Sci. 2014, 126, 183–194.
15. Zhou, S.; Liu, Y.; Prater, K.; Zheng, Y.; Cai, L. Roles of microRNAs in pressure overload- and ischemia-related myocardial remodeling. Life Sci. 2013, 93, 855–862.
16. Aronsen, J.M.; Swift, F.; Sejersted, O.M. Cardiac sodium transport and excitation-contraction coupling. J. Mol. Cell.Cardiol. 2013, 61, 11–19.
17. Bers, D.M. Cardiac excitation-contraction coupling. Nature 2002, 415, 198–205.
18. Bodi, I.; Mikala, G.; Koch, S.E.; Akhter, S.A.; Schwartz, A. The l-type calcium channel in the heart: The beat goes on. J. Clin. Invest. 2005, 115, 3306–3317.
19. Katz, A.M.; Lorell, B.H. Regulation of cardiac contraction and relaxation. Circulation 2000, 102, 69–74.
20. Balaban, R.S. Cardiac energy metabolism homeostasis: Role of cytosolic calcium. J. Mol. Cell. Cardiol. 2002, 34, 1259–1271.
21. 2+in the regulation of cellular energetics. Biochemistry 2012, 51, 2959–2973.
22. 2+. Cell Calcium 2012, 52, 28–35.
23. Porrello, E.R. Micrornas in cardiac development and regeneration. Clin. Sci. 2013, 125, 151–166.
24. Condorelli, G.; Latronico, M.V.; Cavarretta, E. Micrornas in cardiovascular diseases: Current knowledge and the road ahead. J. Am. Coll. Cardiol. 2014, 63, 2177–2187.
25. Weiss, J.B.; Eisenhardt, S.U.; Stark, G.B.; Bode, C.; Moser, M.; Grundmann, S. MicroRNAs in ischemia-reperfusion injury. Am. J. Cardiovasc. Dis. 2012, 2, 237–247.
26. Ye, Y.; Perez-Polo, J.R.; Qian, J.; Birnbaum, Y. The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol. Genom. 2011, 43, 534–542.
27. Gladka, M.M.; da Costa Martins, P.A.; de Windt, L.J. Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. J. Mol. Cell. Cardiol. 2012, 52, 74–82.
28. Dorn, G.W., Jr. Therapeutic potential of microRNAs in heart failure. Curr. Cardiol. Rep. 2010, 12, 209–215.
29. 2+overload. J. Mol. Cell. Cardiol. 2012, 53, 233–239.
30. Kalogeris, T.; Baines, C.P.; Krenz, M.; Korthuis, R.J. Cell biology of ischemia/reperfusion injury. Int. Rev. Cell Mol. Biol. 2012, 298, 229–317.
31. Griffiths, E.J. Mitochondria and heart disease. Adv. Exp. Med. Biol. 2012, 942, 249–267.
32. Walters, A.M.; Porter, G.A., Jr.; Brookes, P.S. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circul. Res. 2012, 111, 1222–1236.
33. Mozaffari, M.S.; Liu, J.Y.; Abebe, W.; Baban, B. Mechanisms of load dependency of myocardial ischemia reperfusion injury. Am. J. Cardiovasc. Dis. 2013, 3, 180–196.
34. Kadenbach, B.; Ramzan, R.; Moosdorf, R.; Vogt, S. The role of mitochondrial membrane potential in ischemic heart failure. Mitochondrion 2011, 11, 700–706.
35. Garcia-Dorado, D.; Ruiz-Meana, M.; Inserte, J.; Rodriguez-Sinovas, A.; Piper, H.M. Calciummediated cell death during myocardial reperfusion. Cardiovasc. Res. 2012, 94, 168–180.
36. Webster, K.A. Mitochondrial membrane permeabilization and cell death during myocardial infarction: Roles of calcium and reactive oxygen species. Fut. Cardiol. 2012, 8, 863–884.
37. Ong, S.B.; Gustafsson, A.B. New roles for mitochondria in cell death in the reperfused myocardium. Cardiovasc. Res. 2012, 94, 190–196.
38. Swaminathan, P.D.; Purohit, A.; Hund, T.J.; Anderson, M.E. Calmodulin-dependent protein kinase ii: Linking heart failure and arrhythmias. Circ. Res. 2012, 110, 1661–1677.
39. Westenbrink, B.D.; Edwards, A.G.; McCulloch, A.D.; Brown, J.H. The promise of camkii inhibition for heart disease: Preventing heart failure and arrhythmias. Expert Opin. Ther. Tar. 2013, 17, 889–903.
40. Anderson, M.E. Camkii and a failing strategy for growth in heart. J. Clin. Invest. 2009, 119, 1082–1085.
41. Anderson, M.E.; Brown, J.H.; Bers, D.M. Camkii in myocardial hypertrophy and heart failure. J. Mol. Cell. Cardiol. 2011, 51, 468–473.
42. 2+/calmodulin-dependent protein kinase II in cardiac hypertrophy and heart failure. Cardiovasc. Res. 2004, 63, 476–486.
43. Backs, J.; Song, K.; Bezprozvannaya, S.; Chang, S.; Olson, E.N. Cam kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J. Clin. Invest. 2006, 116, 1853–1864.
44. Zhang, T.; Kohlhaas, M.; Backs, J.; Mishra, S.; Phillips, W.; Dybkova, N.; Chang, S.; Ling, H.; Bers, D.M.; Maier, L.S.; et al. Camkiidelta isoforms differentially affect calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. J. Biol. Chem. 2007, 282, 35078–35087.
45. Shintani-Ishida, K.; Yoshida, K. Ischemia induces phospholamban dephosphorylation via activation of calcineurin, PKC-alpha, and protein phosphatase 1, thereby inducing calcium overload in reperfusion. Biochim. Biophys. Acta 2011, 1812, 743–751.
46. Gorbe, A.; Giricz, Z.; Szunyog, A.; Csont, T.; Burley, D.S.; Baxter, G.F.; Ferdinandy, P. Role of CGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basic Res. Cardiol. 2010, 105, 643–650.
47. Vila-Petroff, M.; Salas, M.A.; Said, M.; Valverde, C.A.; Sapia, L.; Portiansky, E.; Hajjar, R.J.; Kranias, E.G.; Mundina-Weilenmann, C.; Mattiazzi, A. Camkii inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion injury. Cardiovasc. Res. 2007, 73, 689–698.
48. Tani, M.; Hasegawa, H.; Suganuma, Y.; Shinmura, K.; Kayashi, Y.; Nakamura, Y. Protection of ischemic myocardium by inhibition of contracture in isolated rat heart. Am. J. Physiol. 1996, 271, H2515–H2519.
49. Dou, Y.; Arlock, P.; Arner, A. Blebbistatin specifically inhibits actin-myosin interaction in mouse cardiac muscle. Am. J. Physiol. Cell Physiol. 2007, 293, C1148–C1153.
50. Inserte, J.; Hernando, V.; Garcia-Dorado, D. Contribution of calpains to myocardial ischaemia/reperfusion injury. Cardiovasc. Res. 2012, 96, 23–31.
51. Khalil, P.N.; Neuhof, C.; Huss, R.; Pollhammer, M.; Khalil, M.N.; Neuhof, H.; Fritz, H.; Siebeck, M. Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model. Eur. J. Pharmacol. 2005, 528, 124–131.
52. Sheiban, I.; Tonni, S.; Chizzoni, A.; Marini, A.; Trevi, G. Recovery of left ventricular function following early reperfusion in acute myocardial infarction: A potential role for the calcium antagonist nisoldipine. Cardiovasc. Drugs Ther. 1997, 11, 5–16.
53. Theroux, P.; Gregoire, J.; Chin, C.; Pelletier, G.; de Guise, P.; Juneau, M. Intravenous diltiazem in acute myocardial infarction. Diltiazem as adjunctive therapy to activase (data) trial. J. Am. Coll. Cardiol. 1998, 32, 620–628.
54. Bar, F.W.; Tzivoni, D.; Dirksen, M.T.; Fernandez-Ortiz, A.; Heyndrickx, G.R.; Brachmann, J.; Reiber, J.H.; Avasthy, N.; Tatsuno, J.; Davies, M.; et al. Results of the first clinical study of adjunctive caldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: The randomized multicentre castemi study. Eur. Heart J. 2006, 27, 2516–2523.
55. Jang, I.K.; Weissman, N.J.; Picard, M.H.; Zile, M.R.; Pettigrew, V.; Shen, S.; Tatsuno, J.; Hibberd, M.G.; Tzivoni, D.; Wackers, F.J.; et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (evolve). Am. Heart J. 2008, 155, 113. e1–113.e8.
56. Theroux, P.; Chaitman, B.R.; Danchin, N.; Erhardt, L.; Meinertz, T.; Schroeder, J.S.; Tognoni, G.; White, H.D.; Willerson, J.T.; Jessel, A. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the guardian trial. Guard during ischemia against necrosis (guardian) investigators. Circulation 2000, 102, 3032–3038.
57. Mentzer, R.M., Jr.; Bartels, C.; Bolli, R.; Boyce, S.; Buckberg, G.D.; Chaitman, B.; Haverich, A.; Knight, J.; Menasche, P.; Myers, M.L.; et al. Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: Results of the expedition study. Anna. Thorac. Surg. 2008, 85, 1261–1270.
58. Zeymer, U.; Suryapranata, H.; Monassier, J.P.; Opolski, G.; Davies, J.; Rasmanis, G.; Linssen, G.; Tebbe, U.; Schroder, R.; Tiemann, R.; et al. The Na+/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (escami) trial. J. Am. Coll. Cardiol. 2001, 38, 1644–1650.
59. Kitakaze, M.; Asakura, M.; Kim, J.; Shintani, Y.; Asanuma, H.; Hamasaki, T.; Seguchi, O.; Myoishi, M.; Minamino, T.; Ohara, T.; et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials. Lancet 2007, 370, 1483–1493.
60. Wahlquist, C.; Jeong, D.; Rojas-Munoz, A.; Kho, C.; Lee, A.; Mitsuyama, S.; van Mil, A.; Park, W.J.; Sluijter, J.P.; Doevendans, P.A.; et al. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014, 508, 531–535.
61. Wystub, K.; Besser, J.; Bachmann, A.; Boettger, T.; Braun, T. miR-1/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of myocardin levels during embryonic heart development. PLoS Genet. 2013, 9, e1003793.
62. Curcio, A.; Torella, D.; Iaconetti, C.; Pasceri, E.; Sabatino, J.; Sorrentino, S.; Giampa, S.; Micieli, M.; Polimeni, A.; Henning, B.J.; et al. MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts. PloS ONE 2013, 8, e70158.
63. Shan, H.; Zhang, Y.; Cai, B.; Chen, X.; Fan, Y.; Yang, L.; Chen, X.; Liang, H.; Zhang, Y.; Song, X.; et al. Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling. Int. J. Cardiol. 2013, 167, 2798–2805.
64. Pan, Z.; Sun, X.; Ren, J.; Li, X.; Gao, X.; Lu, C.; Zhang, Y.; Sun, H.; Wang, Y.; Wang, H.; et al. miR-1 exacerbates cardiac ischemia-reperfusion injury in mouse models. PloS One 2012, 7, e50515.
65. Tritsch, E.; Mallat, Y.; Lefebvre, F.; Diguet, N.; Escoubet, B.; Blanc, J.; De Windt, L.J.; Catalucci, D.; Vandecasteele, G.; Li, Z.; et al. An SRF/miR-1 axis regulates NCX1 and annexin A5 protein levels in the normal and failing heart. Cardiovasc. Res. 2013, 98, 372–380.
66. 2+signaling. J. Mol. Cell. Cardiol. 2012, 52, 1027–1037.
67. 2+release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit b56alpha and causing camkii-dependent hyperphosphorylation of RyR 2. Circ. Res. 2009, 104, 514–521.
68. Belevych, A.E.; Sansom, S.E.; Terentyeva, R.; Ho, H.T.; Nishijima, Y.; Martin, M.M.; Jindal, H.K.; Rochira, J.A.; Kunitomo, Y.; Abdellatif, M.; et al. MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PloS One 2011, 6, e28324.
69. 2+overload of cardiomyocytes by targeting camkiidelta. Biochem. Biophys. Res. Commun. 2013, 435, 720–726.
70. Van Rooij, E.; Sutherland, L.B.; Liu, N.; Williams, A.H.; McAnally, J.; Gerard, R.D.; Richardson, J.A.; Olson, E.N. A signature pattern of stress-responsive micrornas that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. USA 2006, 103, 18255–18260.
71. 2+overload and cell death. J. Clin. Invest. 2012, 122, 1222–1232.
72. Wang, X.; Zhang, X.; Ren, X.P.; Chen, J.; Liu, H.; Yang, J.; Medvedovic, M.; Hu, Z.; Fan, G.C. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. Circulation 2010, 122, 1308–1318.
73. Bostjancic, E.; Zidar, N.; Glavac, D. MicroRNAs and cardiac sarcoplasmic reticulum calcium ATPase-2 in human myocardial infarction: Expression and bioinformatic analysis. BMC Genomics 2012, 13, 552.
74. Liu, L.F.; Liang, Z.; Lv, Z.R.; Liu, X.H.; Bai, J.; Chen, J.; Chen, C.; Wang, Y. MicroRNA-15a/b are up-regulated in response to myocardial ischemia/reperfusion injury. J. Geriatr. Cardiol. 2012, 9, 28–32.
75. Hullinger, T.G.; Montgomery, R.L.; Seto, A.G.; Dickinson, B.A.; Semus, H.M.; Lynch, J.M.; Dalby, C.M.; Robinson, K.; Stack, C.; Latimer, P.A.; et al. Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 2012, 110, 71–81.
76. Cheng, Y.; Liu, X.; Zhang, S.; Lin, Y.; Yang, J.; Zhang, C. MicroRNA-21 protects against the H2O2-induced injury on cardiac myocytes via its target gene PDCD 4. J. Mol. Cell. Cardiol. 2009, 47, 5–14.
77. Zhang, X.; Wang, X.; Zhu, H.; Zhu, C.; Wang, Y.; Pu, W.T.; Jegga, A.G.; Fan, G.C. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. J. Mol. Cell. Cardiol. 2010, 49, 841–850.
78. Salic, K.; De Windt, L.J. Micrornas as biomarkers for myocardial infarction. Curr. Atherosclerosis Rep. 2012, 14, 193–200.
79. Reid, G.; Kirschner, M.B.; van Zandwijk, N. Circulating micrornas: Association with disease and potential use as biomarkers. Crit. Rev. Oncol. Hematol. 2011, 80, 193–208.
80. Pegtel, D.M.; Cosmopoulos, K.; Thorley-Lawson, D.A.; van Eijndhoven, M.A.; Hopmans, E.S.; Lindenberg, J.L.; de Gruijl, T.D.; Wurdinger, T.; Middeldorp, J.M. Functional delivery of viral mirnas via exosomes. Proc. Natl. Acad. Sci. USA 2010, 107, 6328–6333.
81. Creemers, E.E.; Tijsen, A.J.; Pinto, Y.M. Circulating micrornas: Novel biomarkers and extracellular communicators in cardiovascular disease? Circ. Res. 2012, 110, 483–495.
82. Kuwabara, Y.; Ono, K.; Horie, T.; Nishi, H.; Nagao, K.; Kinoshita, M.; Watanabe, S.; Baba, O.; Kojima, Y.; Shizuta, S.; et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ. Cardiovasc. Genet. 2011, 4, 446–454.
83. Adachi, T.; Nakanishi, M.; Otsuka, Y.; Nishimura, K.; Hirokawa, G.; Goto, Y.; Nonogi, H.; Iwai, N. Plasma microrna 499 as a biomarker of acute myocardial infarction. Clin. Chem. 2010, 56, 1183–1185.